CA-50 and CA-19.9 as tumour markers: which is preferable?

Area of Science:

• Oncology
• Clinical Chemistry
• Biomarker Research

Background:

• CA-50 and CA-19.9 are established tumor markers.
• Their comparative diagnostic utility, especially in gastro-intestinal (GI) cancers, requires further elucidation.
• Understanding their individual and combined effectiveness is crucial for accurate cancer diagnosis.

Purpose of the Study:

• To prospectively compare the diagnostic performance of CA-50 and CA-19.9.
• To evaluate sensitivities and specificities in cancer patients versus non-neoplastic diseases.
• To assess the correlation and reliability of both markers, particularly in GI malignancies.

Main Methods:

• Prospective study involving 323 cancer patients (56% metastatic) and 120 patients with benign diseases.
• Assay of serum CA-50 and CA-19.9 levels using specific diagnostic kits.
• Statistical analysis to compare sensitivities, specificities, and correlations between markers.

Main Results:

• CA-50 exhibited higher sensitivity (41.8%) than CA-19.9 (39%) overall.
• CA-50 showed significantly greater sensitivity in GI tract cancers (61.3% vs. 51.6%).
• CA-19.9 demonstrated higher specificity (77.5% vs. 64.2%), particularly in respiratory diseases.
• A strong positive correlation was observed between CA-50 and CA-19.9 serum levels in both cancer (r=0.78) and benign disease groups (r=0.69).

Conclusions:

• CA-50 and CA-19.9 are highly correlated and demonstrate similar reliability, especially for GI cancers.
• Both markers are effective for detecting gastro-intestinal malignancies.
• Simultaneous measurement of CA-50 and CA-19.9 is deemed redundant due to their strong correlation and overlapping diagnostic utility.